Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal


Author index

Page Path
HOME > Browse articles > Author index
Young-Rak Cho 1 Article
Efficacy of Evolocumab in Patients with Hypercholesterolemia
Xuan Jin, Moo Hyun Kim, Young-Rak Cho, Jong-Sung Park, Kai Song, Song Lin Yuan
Kosin Med J. 2020;35(2):125-132.   Published online December 31, 2020
  • 1,176 View
  • 14 Download
  • 1 Citations
Abstract PDFPubReader   ePub   

The FOURIER trial reported that inhibition of PCSK9 with evolocumab on a background of statin therapy lowered low-density lipoprotein (LDL) cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. Here, we report data from a single center focusing on the effect of a PCSK9 inhibitor antibody on hyperlipidemia.


We enrolled 29 hypercholesterolemia patients who had LDL cholesterol levels ≥ 70 mg per deciliter or non-HDL cholesterol ≥ 100 mg per deciliter and were divided into two groups (placebo n = 14, evolocumab n = 15), and participated in a 72 – 96 week, randomized, double-blind, placebo-controlled trial with statin therapy. Patients were randomly assigned to receive evolocumab (140 mg every 2 weeks or 420 mg monthly) or matched placebo via subcutaneous injection. Lipid changes during follow-up were analyzed.


The median LDL cholesterol level at baseline was 88 mg per deciliter, and the average LDL cholesterol level was 101.8 ± 20.0 mg per deciliter. At 4 weeks, the median LDL cholesterol level was 39 mg per deciliter, and the average LDL cholesterol level was 34.8 ± 51.8 mg per deciliter. Compared to placebo group, the LDL cholesterol levels were significantly reduced after treatment (P < 0.001), as well as total cholesterol, ApoB, and ApoB/ApoA1 levels. During follow-up, no discomfort was reported at local injection sites, and no cases of abnormal liver function were observed.


Evolocumab significantly reduced LDL cholesterol levels and was well tolerated.


Citations to this article as recorded by  
  • Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
    Bee Ling Kelly Chng, Wei Min Paul Heng, Yu Ming Soon, Jin Shing Hon, Yee How Lau, Ru San Tan, Jack Wei Chieh Tan
    Proceedings of Singapore Healthcare.2022; 31: 201010582211441.     CrossRef

KMJ : Kosin Medical Journal